Navigation Links
Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
Date:7/9/2008

eviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic range of APD791 and the exposures which may produce minimal, moderate or near-complete inhibition of serotonin-mediated amplification of platelet aggregation; the potential for APD791 to provide advantages over currently available therapies; determination of the best approach to advance APD791 into Phase 2 clinical trials; the tolerability, side effects and efficacy of APD791; the role of serotonin in thrombosis and in increasing cardiovascular risk; how APD791 is believed to work and its intended use and therapeutic potential; and about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's planned clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings w
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
2. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
3. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
6. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
7. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
8. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
9. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
10. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
11. Isis Pharmaceuticals Conference Call Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  The need to add tissue preserving therapies ... prominently at the 108 th Annual Meeting ... Diego.  According to SonaCare Medical, a leader in ... the need for image-guided technologies to better identify ... minimally invasive ablative treatments, was addressed in the ...
(Date:5/23/2013)... 23, 2013  Every day, their baby stopped breathing, his ... lungs. April and Bryan Gionfriddo watched ... "Quite a few doctors said he had a ... April Gionfriddo , about her now 20-month-old son, ... work, we would take it and run with it." ...
(Date:5/23/2013)... Mass. , May 23, 2013  Hologic, ... HOLX ), a leading developer, manufacturer and supplier ... products, with an emphasis on serving the healthcare ... large-scale observational study in a U.S. clinical practice ... technology (breast tomosynthesis) with conventional 2D mammography alone ...
Breaking Medicine Technology:Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4
... , , , , , , CAPUA, ... has entered into an agreement with Laboratoires Mayoly Spindler, Chatou ... has successfully completed process development and commenced cGMP manufacture of ... clinical needs. DSM BioSolutions manufactures the lipase compound at its ...
... , ALISO VIEJO, Calif., Dec. 21 Clarient, Inc. (Nasdaq: ... pathologists, oncologists and the pharmaceutical industry, today announced that it ... in an all-stock merger valued at up to $17.6 million, ... agreement are successfully met. As a result of the ...
Cached Medicine Technology:DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 2DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 3DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 4Clarient Acquires Applied Genomics, Inc. 2Clarient Acquires Applied Genomics, Inc. 3Clarient Acquires Applied Genomics, Inc. 4Clarient Acquires Applied Genomics, Inc. 5Clarient Acquires Applied Genomics, Inc. 6Clarient Acquires Applied Genomics, Inc. 7
(Date:5/24/2013)... (PRWEB) May 24, 2013 HCG EZ Drops ... and is excited to announce it’s new weight loss initiative. “We ... we are offering our customers their money back if they don’t ... CEO of HCG EZ Drops. “The HCG Diet consists of ... the 21 pounds in 21 days.” , The controversial, cutting-edge diet ...
(Date:5/24/2013)... The leading retail brand Short Dresses ... prom dresses . Now that is quite unbelievable, especially in ... brand name since its origin. The retailer has already revealed ... this huge discount offer will be an added bonanza for ... privileged to announce that Short Dresses is to offer different ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Over the ... been gradually transforming, which has affected the Medical ... debt and seeking regular hours, more young physicians are ... or other medical groups,” says IBISWorld industry analyst Anna ... reimbursement pressure, a number of older physicians are selling ...
(Date:5/23/2013)... High blood glucose is associated with poor outcomes in ... to control hyperglycemia is a common practice in hospitals. ... benefit and even shows harms associated with the use ... (ACP) Clinical Guidelines Committee in a new evidence-based paper ... Medical Quality . , "Clinicians caring for hospitalized patients ...
(Date:5/23/2013)... 2013 The sodium theory ... and B. Katz in the early 1950s, after their ... of sodium and potassium ions in nerve functions ... acquisition techniques have known amazing developments. In The Sodium ... give an account of the latest developments in the ...
Breaking Medicine News(10 mins):Health News:short prom dresses Offers Abnormally Low Discount on Its New Collections 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 3Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 2Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 3
... The Journal of the American Dental Association ... in publishing a global theme issue on poverty ... the worlds biomedical publications., The Council of Science ... simultaneous publication by science journals throughout the world ...
... Medical Center may have solved the mystery surrounding the healing ... interest in gold salts as a treatment for rheumatoid arthritis ... gold salts in the early 1900s to ease the pain ... a high cost: The shots took months to take ...
... Sponsored by Health Improvement Institute, Consumer,Reports WebWatch, ... is organizing a one-day workshop Monday, November 12,to ... Internet., Held at the Hyatt Regency Hotel ... health experts, representatives of relevant,organizations, and consumers to ...
... Pre-Emption in Riegel v. Medtronic, Inc., WASHINGTON, Oct. ... Medical Technology Association,(AdvaMed) filed a joint amicus brief Friday ... v. Medtronic, Inc. arguing that the FDA should,continue to ... states that,no other legislative or regulatory entity is better ...
... J. Halamandaris,President of the National Association for Home Care ... the power of caring, both at home,and in their ... Hospice Month., "It is highly appropriate that we ... nurses, therapists, aides and other providers who have chosen,to ...
... publisher, is proud to be participating in a Global ... by the Council of Science Editors. , The CSE ... interest and debate on the crucial matters of poverty ... developed and developing countries will simultaneously publish papers on ...
Cached Medicine News:Health News:Journal of the American Dental Association spotlights poverty 2Health News:Scientists discover how gold eases pain of arthritis 2Health News:Can the Web Transform the U.S. Healthcare System? 2Health News:Can the Web Transform the U.S. Healthcare System? 3Health News:Amicus Brief Filed with U.S. Supreme Court in Riegel v. Medtronic, Inc. 2Health News:U.S. Celebrates National Home Care and Hospice Month in November 2Health News:9 SAGE journals participate in global theme issue on poverty and human development 2
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Endotracheal Tube Stylet- Adult, Copper, Malleable, Non-Sterile, Latex Free, Suitable for tubes 5.0 mm I.D. or larger....
... Prevent dental and soft tissue damage. Used ... X-ray. Light-guided intubation is based upon the ... neck. This technique takes advantage of the ... the esophagus. A well-defined, circumscribed glow can ...
Medicine Products: